We serve Chemical Name:methyl 4-bromo-3-hydroxy-5-methylthiophene-2-carboxylate CAS:113589-26-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:methyl 4-bromo-3-hydroxy-5-methylthiophene-2-carboxylate
CAS.NO:113589-26-7
Synonyms:2-Thiophenecarboxylic acid,4-bromo-3-hydroxy-5-methyl-,methyl ester;methyl 4-bromo-3-hydroxy-5-methyl-2-thiophenecarboxylate
Molecular Formula:C7H7BrO3S
Molecular Weight:251.09800
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:74.77000
Exact Mass:249.93000
LogP:2.31120
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-Thiophenecarboxylic acid,4-bromo-3-hydroxy-5-methyl-,methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 4-bromo-3-hydroxy-5-methyl-2-thiophenecarboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 4-bromo-3-hydroxy-5-methyl-2-thiophenecarboxylate Use and application,2-Thiophenecarboxylic acid,4-bromo-3-hydroxy-5-methyl-,methyl ester technical grade,usp/ep/jp grade.
Related News: That site will also tap robotics and virtual reality training, which Takeda says should help operators “learn in a virtual environment before they enter the real facility.” 6-(4-(2-(piperidin-4-ylamino)ethyl)phenyl)pyridin-2-amine trihydrochloride manufacturers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. (E/Z)-Trelnarizine suppliers A new post-hoc analysis of pooled data from the TULIP phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus (SLE). 2-methyl-2-(4,7,7-trimethyl-5-bicyclo[4.1.0]hept-3-enyl)-1,3-dioxolane vendor & factory.
